Ophthalmology Times Europe
SEARCH
  • home
  • about us
  • contact us
  • subscribe
  • media kit request
 

CATARACT

GLAUCOMA

REFRACTIVE

RETINA

Previous StoryPlay / PauseNext Story
Latest cataract news
Oertli launches next generation microincision instruments
July 8, 2008
Oertli has launched new instruments to be used in microincision surgery for the anterior and the posterior segments.
Fourth-generation accommodating IOL gets FDA ok
July 8, 2008
The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market.
Alcon and AMO to cross-license IOL patents
June 30, 2008
Alcon and Advanced Medical Optics (AMO) are to share proprietary information on their designs for intraocular lenses (IOL).
Postoperative pain steroid approved
June 30, 2008
Durezol (difluprednate ophthalmic emulsion; Sirion Therapeutics) 0.05%, a topical steroid, has received US Food and Drug Administration (FDA) approval for the treatment of postoperative ocular inflammation and pain.
NSAID activity at trough drug levels
June 23, 2008
Animals undergoing lens removal surgery were treated with non-steroidal anti-inflammatory drugs pre- and postoperatively. On the first day after surgery, aqueous humor samples were taken at times corresponding to trough drug levels. The mean aqueous prostaglandin E2 concentration was significantly lower in animals being treated with ketorolac 0.4% (Acular LS, Allergan) compared with those receiving bromfenac 0.09% (Xibrom, ISTA Pharmaceuticals).
Cataract articles
Study evaluates safety of intracameral moxifloxacin
June 30, 2008
The safety of intracameral moxifloxacin (Vigamox, Alcon Laboratories) for post cataract surgery endophthalmitis prophylaxis was investigated in a prospective, randomized, controlled study. Statistical analyses of multiple postoperative outcome measures demonstrated no significant differences between patients who received intracameral moxifloxacin and controls treated with intracameral balanced salt solution.
Ophthalmologists' priorities are changing
June 2, 2008
A 2006/2007 survey gauged the opinions and practice styles of 1 093 ophthalmologists in France. Here are the results.
Arsenal of strategies enables safe surgery in IFIS eyes
April 21, 2008
Cases of intraoperative floppy iris syndrome (IFIS) encompass a wide spectrum of severity, so it is important for surgeons to master several different strategies to increase the likelihood of achieving a safe outcome in these eyes.
We have microincisions & now we have a suitable IOL
April 1, 2008
I have been so impressed with the aspheric optics and good centration of the Akreos MI60 that I use it as my first choice for implantation; including in patients with visual-critical occupations such as aviators and air traffic controllers
Microincision IOLs go head-to-head
April 1, 2008
Nowadays, cataract surgery not only has a therapeutic purpose, which is to substitute an opaque lens with a transparent IOL, but it also has a refractive aim; to correct previous refractive defects in order to eliminate the use of spectacles. The need for a good postoperative visual acuity and a fast functional recovery has lead cataract surgery to become more and more micro-invasive in nature so that surgical trauma is reduced, a faster recovery and good, time-stable visual results are achieved.1 The achievement of this goal has been realized, thanks to the improvement of surgical techniques, in the form of microcoaxial phacoemulsification and bimanual microphacoemulsification,2 which now allow the almost complete reduction of surgically induced astigmatism.
A special online feature looking at all the latest developments in IOLs.
Newsletter sign-up
CO-MICS special report: part 1
Coaxial microincision cataract surgery: the future is small
CO-MICS special report: part 2
Special feature asks the question: is the future small?
Survey
Do you use intracameral antibiotics in all of your cataract surgeries?
Always
Never
Sometimes
Rarely
Always
55%
Never
18%
Sometimes
23%
Rarely
5%
View Results
Thank you!
Call for papers

Click here to discover how you can have your say

Click here